Thus, FGFR1 is considered as an attractive tumor biomarker and several approaches for selective treatment of FGFR1 overproducing cancer cells have been developed, including cytotoxic conjugates with antibody fragments or natural ligands as targeting agents [22–25]. The gene discussed is FGFR1; the disease is cancer.